Why The UK Started Screening Every Child For Type 1 Diabetes

Sophie was on holiday when she became so dehydrated she could barely stand. Her parents thought she had a stomach bug. By the time doctors stabilised her blood sugar, she was in diabetic ketoacidosis, a life-threatening condition that occurs when the body starts shutting down for lack of insulin. She spent three days in intensive care.

Sophie's story is not unusual. Across the UK, over a quarter of children are not diagnosed with type 1 diabetes until they reach this crisis point [1]. The condition has already been damaging their body for months, sometimes years, before anyone realises what is happening. A simple finger-prick test could have changed everything.

That is exactly what a landmark study has now proven.

The Study That Changed Everything

In 2022, researchers at the University of Birmingham launched the ELSA study, the first UK investigation of its kind into population screening for type 1 diabetes in children [1]. The name stands for Early Surveillance for Autoimmune diabetes. The goal was ambitious: to determine whether catching the disease before symptoms appear could prevent thousands of emergency diagnoses each year.

More than 37,000 families signed up by November 2025 [1]. Children aged 3 to 13 were tested using a finger-prick test that checks for autoantibodies, markers of type 1 diabetes that can appear years before any symptoms develop. The test can be done at home, in school, or at a GP surgery [2].

The first phase results, published in The Lancet Diabetes & Endocrinology, have now put the UK on the brink of a historic policy shift [2].

What the Numbers Show

Of the 17,283 children screened in the initial phase, the results were striking. Seventy-five children had one autoantibody present, which carries roughly a 15 percent chance of developing type 1 diabetes within the next decade [1][2]. One hundred and sixty children had two or more autoantibodies, meaning their immune system had already begun attacking the insulin-producing cells in their pancreas [1][2]. Seven children had undiagnosed type 1 diabetes requiring immediate insulin [1].

Those seven children were diagnosed before they ended up in crisis. Their families had time to learn, to prepare, and to start treatment while the condition was still manageable rather than a medical emergency.

The data also confirmed something that makes targeted screening impossible: in more than 85 percent of childhood type 1 diabetes cases, there is no family history of the disease [1][2]. This means you cannot rely on whether anyone's grandmother had it. Population-wide screening is the only way to catch most of these children early.

A Drug That Changes the Timeline

Until recently, an early diagnosis was useful mainly for avoiding DKA. That changed in August 2025 when the MHRA approved teplizumab, the first-ever immunotherapy for type 1 diabetes [3]. The drug can delay the need for insulin by approximately three years [1][3]. It works by reprogramming the immune cells that attack the pancreas, essentially buying children time before their insulin production is permanently compromised.

The first UK patient treated with teplizumab was at Birmingham Children's Hospital [1]. NICE is currently assessing whether to recommend the drug for NHS use in England and Wales [1][3].

For children identified through screening, this changes the calculus entirely. They are not just being diagnosed early to avoid a hospital emergency. They may also be eligible for a treatment that fundamentally alters the course of their disease.

The Road to Universal Screening

The ELSA study is not finished. A second phase, ELSA 2, aims to recruit 30,000 additional children aged 2 to 17 [1]. Italy already screens children aged 1 to 17 for type 1 diabetes [2], giving the UK a working model to study and potentially adapt.

The ultimate decision on whether to adopt universal screening in the UK will rest with ministers, advised by the UK National Screening Committee [1]. The ELSA results provide the most robust evidence yet that population screening is both feasible and effective. Whether that evidence translates into policy will depend on factors beyond the science, including cost, infrastructure, and how quickly the healthcare system can build capacity for the kind of nationwide programme that would be needed.

What is clear is that the medical case has been made. Screening can prevent children from ending up in intensive care. It can give families time to understand their child's condition before a crisis forces them to learn everything at once. And now, with teplizumab available, it can identify children who may benefit from a treatment that delays the most severe impacts of the disease by years.

The question is no longer whether screening works. It is how quickly the UK can make it available to every child who needs it.

Parents should consult their GP about any concerns regarding their child's health or diabetes risk. This article does not constitute medical advice.